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CRANIOMETAPHYSEAL DYSPLASIA: THE NEED FOR A NATURAL 
HISTORY OF DISEASE STUDY 
 
MICHAEL ANIL PERSAUD 
ABSTRACT 
  Craniometaphyseal dysplasia (CMD) is a rare genetic skeletal disorder, whose 
biological understanding is not very well known.  The disease manifests itself through 
bony hypertrophy of the skull base, craniofacial bones, and abnormal morphology of the 
long bones, present in the carrier of the disease.  CMD has been previously determined 
through genetic analysis to be a result of one of 15 (to date) discovered mutations.  
Fourteen of those mutations are inherited in an autosomal dominant fashion, via 
mutations in the ANKH gene.  One mutation has been discovered to result in CMD 
through autosomal recessive inheritance, via a locus found in the connexin 43 gene, 
coding for gap junction protein alpha-1.  As the genetic foundation of CMD has become 
more clearly understood over time, there has been a lack of similar progress in 
understanding the clinical manifestations of CMD.  To improve our understanding of the 
clinical characteristics of CMD, we propose a natural history of disease study to be 
conducted.  This study serves as a pilot for this larger scale study, by using a smaller 
patient population comprised of CMD patient database at the Reichenberger Lab at 
University of Connecticut Health (UCH), and CMD patients reported in the literature, to 
understand what is currently known about the clinical manifestations of CMD, and what 
should be evaluated for further research.   
		 vii 
In this study, the existing literature on CMD has been compiled and sorted into 
distinct groups – created to guide those unfamiliar to the disease through the available 
information.  Secondly, a set of 76 patient cases compiled at the Reichenberger lab at 
UCH were analyzed to determine what clinical information on CMD has already been 
collected.  Lastly, from an in depth analysis of two specific case files from the 
Reichenberger Lab CMD patient database it was discovered that blood chemistry levels 
are an important parameter for analysis in future studies.   
From abnormalities in blood chemistry within both cases were found. . In both 
patients it was found that elevations in serum alkaline phosphatase were present 
congenitally, and persisted throughout the early childhood years.  Specific attention to 
changing serum alkaline phosphatase concentrations over early childhood development is 
recommended.   
Additionally, from data present in patient case 2, blood urea nitrogen 
(BUN/creatinine) was found to be highly elevated through early childhood, though 
eventually slowly decreasing to the upwards bounds of the normal physiological 
reference range, by the time the patient grew from ages 1 to 12. No BUN/Creatinine data 
was provided by the first case.  
Lastly, from an analysis of the literature, the patient case files at the 
Reichenberger lab at UCH and an in depth study of two specific patient cases a list of 
clinical parameters useful for investigation in a full-scale natural history of disease study 
of CMD is presented. 
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INTRODUCTION 
Craniometaphyseal dysplasia 
 Craniometaphyseal dysplasia (CMD) is a rare genetic disorder, resulting in 
abnormalities in bone formation and mineralization of the skeleton.  With fewer than 200 
reported cases in the literature, CMD is a disease that is extremely rare and little 
researched. 
 First identified as its own disease entity by Jackson in 1954 [37], 
craniometaphyseal dysplasia is a genetic disorder leading to a specific display of bony 
overgrowth and sclerosis.  Most notable is the bony overgrowth of the skull base, 
hyperostosis of the craniofacial bones, and the characteristic widened metaphyses of the 
long bones [37].  Individually, each symptom could be explained by a separate respective 
disease – osteopetrosis (sclerosis of the base of the skull) and metaphyseal dysplasia, as 
seen in Pyle’s Disease (flaring of the metaphyses of the long bones).  Jackson found 
enough clinical evidence, however, to determine the presence of a distinctly separate 
disease he termed “craniometaphyseal dysplasia.” [37] 
 Currently, there exist over 500 reported different types of rare genetic bone 
disorders [11].  Within these rare genetic bone disorders, CMD falls in a specific 
classification of the various craniotubular dysplasias (CTD), a subset of the 
osteochondrodysplasias.  Even within the classification of CTDs, these rare bone diseases 
contain varying non-specific clinical manifestations, making diagnosis of each of the rare 
bone disorders complicated and subject to misinterpretation [59].  With an expansive 
range of skeletal disorders from which a patient may be suffering, it is important to 
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distinguish each disorder’s pathogenesis for proper diagnosis and development of 
appropriate treatment plans. 
 Despite over 50 years of clinical studies on CMD, there has never been definitive 
research investigating CMD for developing both guidelines and standardized procedures 
for diagnosis and treatment of the disease.  For many of the other rare bone diseases, the 
situation seems to be the same – there is no definitive study informing of the disease, for 
patients or physicians to refer to.  Without CMD guidelines for physicians, patients 
presenting with clinical signs of CMD may be misdiagnosed due to both physician 
unfamiliarity with the disease, and the commonalities between CMD and other rare bone 
disorders.  Without a set of guidelines for patients with the disease, patients may not be 
able to understand progression of the disease, factors for acquiring and transmitting the 
disease, as well as the varying options for treatment and therapy.  Lastly, without detailed 
knowledge of molecular mechanisms that lead to CMD, pharmaceutical companies do 
not have a foundation to study molecular targets for development of therapeutics. 
 To combat this lack of CMD awareness, a natural history study is proposed.  A 
natural history study of CMD seeks to understand the etiology, manifestations and 
progression of CMD across a sample population.  Currently, the Reichenberger Lab at 
University of Connecticut Health (UCH) in Farmington, CT, is researching the genetics 
and molecular biology associated with CMD.  A relatively large CMD patient population 
has been screened and the data pooled for use in separate studies.  From the collected 
data, a pilot natural history study of CMD is conducted to compare disease history, 
disease progression, diagnostic parameters, blood chemistry and genetic composition.  
	3 
 The data from this pilot study will set the foundation for a future large scale 
natural history study, which may then be used to produce recommendations that may 
include diagnosis, prognosis of disease progression and treatment - for distribution to 
both patients with the disease, and physicians who may encounter or diagnose the 
disease.  By conducting this study and developing a report, the physiological and social 
ramifications of CMD will be better understood, allowing for more accurate differential 
diagnosis of CMD.  
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BACKGROUND 	
Clinical manifestations 
 Patients diagnosed with craniometaphyseal dysplasia present to the clinic a 
diverse array of signs and symptoms depending on the severity of the disease, and age of 
the individual. Craniometaphyseal dysplasia has been reported to occur in both autosomal 
dominant (AD) and autosomal recessive (AR) forms.  It is known that in AD-CMD, the 
transmission of the genotype from parent to child is complete (further explained in the 
“Genetics of CMD” section), however, phenotypic expressivity of the disease is 
demonstrated to vary between patients with identical mutations [62]. CMD does not have 
a specifically defined pathology, and biochemistry of the disease is not currently 
completely understood.  What is known, however, is that patients diagnosed with CMD 
develop either some, or all, of a set of noticeable pathognomonic physical characteristics. 
 Of the clinical manifestations of craniometaphyseal dysplasia, many are apparent 
through clinical observation.  Patients with CMD often present dysmorphic craniofacial 
features, including: macrocephalus, ocular hypertelorism, wide nasal bridge, frontonasal 
bossing, prominent mandible, and partial facial nerve paralysis (Figure 1). 
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Figure 1:  Clinical presentation of craniometaphyseal dysplasia. 
Depicted above is a 21 year old male patient diagnosed with craniometaphyseal 
dysplasia.  In this image, examples of the dysmorphic facial features of CMD patients are 
shown.  From the frontal profile (R) ocular hypertelorism is noticeable, as well as a very 
wide nasal bridge, flattening out the center of his face.  From the side profile (L) 
frontonasal bossing can be seen, as well as the prominence of his mandible.  
Macrocephalus is also noticeable in the patient, where the cranial circumference exceeds 
the normal physiological range. 
 
(Figure taken from [38]) 
 
 Clinical manifestations of craniometaphyseal dysplasia may relate to the length of 
time an individual has lived with the disease, the severity of the disease (whether AD or 
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AR form), and how their body has compensated to the disease.  In younger patients such 
as infants, CMD can present itself through nasal obstruction due to sclerosis of the nasal 
choanae [72].  As children get older, narrowing of the cranial foramen caused by bone 
overgrowth (hyperostosis) can compress nerves and result in gradually degrading visual 
and auditory perception, as well as partial facial paralysis or facial palsy [74].  
 Along with changes in formation of the craniofacial bones, CMD is also 
responsible for flaring in the metaphyses of long bones.  This is commonly referred to as 
the “Erlenmeyer flask” shaping of long bone metaphyses, where the metaphyses appears 
to be widened on both ends, this reducing the length of long bone diaphysis.   In a study 
of CMD comparing wild type mice and mice with a knock-in mutation (Phe377 del) in 
ANKH, it was found that mice containing the ANKH mutation displayed more 
trabeculation within the diaphyses of the long bones, however, less trabeculation in the 
metaphyses [14].  Differences in disease characteristics and pathophysiological 
manifestations between the mouse model and AD-CMD patients containing the same 
mutation (Phe377del) are thought to be due to phenotypic thresholds specific to each 
species, dependent on lifestyle and lifespan. 
 Though primarily a skeletal disorder, patients may enter the clinic presenting with 
neurological symptoms.  CMD’s increased bone deposition leads to the progressive 
thickening of the craniofacial skeleton throughout life.  Foramina within the skull reduce 
in size and compress cranial nerves.  Often, patients present with lost or reduced bilateral 
vision and bilateral hearing due to the obstruction of the optic, oculomotor, trochlear and 
abducens nerves (Cranial Nerve (CN) II, CN III, CN IV, CN VI) and vestibulocochlear 
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nerve (CN VIII), respectively [64].  Additionally, patients may also present with partial 
paralysis of the facial muscles, due to compression of the facial nerve (CN VII).  If left 
untreated, these neurological deficits can become severe, leading to: partial or complete 
bilateral blindness and/or deafness, motor deficits, facial pain and facial palsy [38].  
Severe neurological complications in CMD are found more often in patients diagnosed 
later in life, where surgical or therapeutic intervention has not been provided at an earlier 
age. 
 Alongside increased pressure on the cranial nerves due to narrowing of cranial 
foramina, exists the risk of increased pressure on the entire brainstem and spinal cord, 
due to narrowing of the foramen magnum.  This condition is referred to as a Chiari I 
malformation, and is sometimes found syndromic with CMD.  In Chiari I malformation, 
crowding within the lower base of the skull can result in the cerebellar tonsils pushing 
through the skull base and onto the spinal canal.  These herniated tonsils will block the 
flow of cerebrospinal fluid (CSF).  The resulting increased intracranial pressure (ICP) 
will exacerbate the cerebellar tonsils to move even further down, increasing pressure on 
the brainstem and cervical spinal cord.  Symptoms of Chiari I malformations present in 
late childhood as severe headaches, dizziness and in severe cases, paraplegia of the arms 
and reduced sensation of the hands [7]. 
Diagnostic considerations 
 Currently, there are no published guidelines for the diagnosis of 
craniometaphyseal dysplasia.  Information on the disease is sparse, and thus many 
physicians may be unaware of the disease for consideration in diagnosis.  In the literature, 
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initial diagnosis of CMD has been made at a wide range of ages [21, 46].  Diagnosis may 
be further complicated in some patients with prior misdiagnosis of separate rare skeletal 
disorders or other ailments.  Differential diagnosis of craniometaphyseal dysplasia 
reported in the literature has been made in subjects ranging from infancy to adulthood.   
 Due to the overlapping clinical manifestations of many rare bone diseases, 
diagnosis of CMD cannot be made based on clinical observation alone.  Diagnosis of 
CMD is made predominantly based on patient bone structure, seen through computed 
tomography (CT) and magnetic resonance (MR) imaging.  Specifically, within CMD 
patients, physicians must identify the presence of both a thickened craniofacial skeleton, 
and flared metaphyses within the long bones (Figure 2 & Figure 3).  Since either 
hyperostosis of the cranial bones or flared metaphyses alone are not specific to any one 
rare bone disease, differential diagnosis between these diseases can become difficult for 
physicians [62].  It is important that both conditions are displayed via radiographic 
imaging for the diagnosis to be made.  Additional less common radiographic findings 
include sclerosis along both the skull sutures, and the petrous region of the temporal bone 
[49].  
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Figure 2: Flared metaphyses of long bones in craniometaphyseal dysplasia. 
CT imaging of both femurs in a 4-year-old female patient diagnosed with CMD.  Note 
the flared “Erlenmeyer flask” shape of the femoral metaphyses.  
(Image taken from [43]) 
 
 
Figure 3:  Thickened craniofacial skeleton in craniometaphyseal dysplasia. 
CT image identifying the thickened cranium of a 15-year-old female patient with 
craniometaphyseal dysplasia.  A significant thickening of the cranium is noticeable, 
decreasing the volume available for the enclosed brain. 
(Image taken from [20]) 
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 Differential diagnosis is extremely important between rare skeletal disorders, 
because of their many overlapping clinical manifestations and characteristics[24].  
Knowing specifically which of the rare skeletal disorders a patient should be diagnosed 
with is important for predicting the disease progression.  One disorder popularly confused 
with CMD is craniodiaphyseal dysplasia (CDD). CDD is associated with a widening of 
the diaphyses instead of metaphyses, causing long bones to take on a cylindrical shape 
resulting from sclerosis of the cortical bone [6].  Another disorder commonly 
misdiagnosed as CMD, is metaphyseal dysplasia or Pyle’s disease.  The important 
distinction with Pyle’s disease is that unlike CMD, hyperostosis of the skull base rarely 
occurs.  A third disease subject to misdiagnosis is frontometaphyseal dysplasia (FMD).  
FMD contains similar manifestations as CMD, however it also exhibits hypertrophy of 
the supraorbital ridges, deficient mandibular growth, and both narrow ribs and pelvis 
[60].  FMD patients develop alterations of the digits, vertebrae, iliac crest and pelvis, in 
addition to CMD’s characteristic craniofacial and long bone deformations [60].  Along 
with help for differential diagnosis, CT and MR imaging are also encouraged to analyze 
the impact the disease has made on the patient’s central nervous system (CNS) and 
cranial vasculature. 
 When used alongside clinical observations, molecular diagnosis is a valuable tool 
to confirm CMD.  Prenatal diagnosis of CMD can be made by genetic analysis, however 
this is only possible if the mutation runs within the family (not reliable for sporadic 
cases).  With known mutations already discovered and listed in the Human Gene 
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Mutation Database (HGMD), cross-referencing mutations may help confirm CMD when 
making a differential diagnosis.  Occasionally, ultrasound scans in utero may also be 
indicative towards the presence of CMD, however this is not as reliable for diagnosis, 
when compared to genetic and biomolecular analysis [87]. 
Genetics of CMD 
 Craniometaphyseal dysplasia is a genetically inherited disease [55, 62].  
Craniometaphyseal dysplasia has been reported to occur in both autosomal dominant 
(AD) and autosomal recessive (AR) forms.   
 The AD form of CMD appears more commonly in the literature and historically 
has been mistakenly reported as the less severe form of the two.  The dominant 
inheritance of AD-CMD has been proven to be dissimilar to the recessive inheritance of 
the related skeletal disorder metaphyseal dysplasia, or Pyle’s Disease [27].  In the AD 
form of CMD it has been found that mutations in cytoplasmic regions close to the C-
terminus of the human ANK gene (ANKH) product result in CMD [62].  AD-CMD and 
mutations of the ANKH gene have been linked to the chromosome region 5p15.2-p14.1 
occurring usually between exon 7 and exon 10 of the ANKH gene, relating to 
transmembrane regions close to the C-terminus of the transmembrane protein [55, 62].  
Separate mutations of the ANKH gene have also been reported in cases of 
chondrocalcinosis, and in CMD patients with comorbid chondrocalcinosis [2].  The 
distinguishable difference, however, seems to be that mutations in ANKH exons 7-10 
cause CMD, whereas mutations in exons 1 and 2 lead to chondrocalcinosis [21]. 
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 The ANK gene is highly conserved amongst vertebrates, exemplifying its 
importance through genetic inheritance [32].  The ANK protein resulting as the ANK 
gene product has not yet been definitively discovered in terms of topology and protein 
structure.  Though the ANKH protein has not been crystallized, several computer model 
predictions exist [45].  There is currently debate regarding the number of transmembrane 
loops in available computer models of the ANKH protein.  From murine studies of the 
homologous mouse ANK gene, it is known that the ANKH protein acts as a 
pyrophosphate transporter, moving pyrophosphate across the plasma membrane from the 
intracellular to extracellular domain [32].  Though this study concentrates on the role of 
ANKH in bone formation, ANK expression has also been identified in neuronal pathways 
within the brain [86]. 
 Regulation between extracellular pyrophosphate (ePPi), intracellular 
pyrophosphate (PPi) and inorganic phosphate (Pi) is important in regulating bone mineral 
content homeostasis.  Normal ePPi at physiological levels will inhibit mineralization, 
whereas low ePPi will increase hydroxyapatite (HA) deposition.  High ePPi levels as seen 
in chondrocalcinosis patients can increase formation of calcium pyrophosphate dehydrate 
(CPPD) in joints [15].  A buildup of ePPi can be detrimental in leading to ectopic 
mineralization in joints and the formation of osteophytes in joints [29].  Along with ANK, 
bone content and phosphate levels are additionally regulated by proteins PC-1, (plasma 
cell glycoprotein 1) which creates PPi from nucleoside phosphates (NTP), and TNAP 
(tissue non-specific alkaline phosphatase), which hydrolyzes ePPi to Pi.  Deficiency in 
any of these three genes or gene products have been shown to produce abnormal bone 
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mineral content, due to their participation in regulating the ePPi and PPi physiological 
homeostasis [15]. 
 Independent mouse studies of the murine ANK homolog have been conducted to 
show the significance of ANK mutations in producing physiology similar to humans 
diagnosed with CMD.  Comparisons were made between CMD patients containing a 
single point mutation in the ANKH gene (Phe377del), and mice treated to have a knock-
out (KO) mutation of their ANKH gene.  It was found that in humans with mutated ANKH 
and mice with knock-out ANK, there are increases in skull thickness, narrowing of the 
foramen magnum leading to compression on the brainstem, and a decrease of bone 
trabeculae found in the metaphyses of the femur [29].  Absent from the mouse KO-ANK 
condition, however, are the hypertrophy of nasal choanae, blocking of nasal sinuses, 
ocular hypertelorism, and flaring of metaphyses of the long bones, such as the femur – 
conditions all found in CMD patients with mutated ANKH genes.  From this, it has been 
concluded that the human homolog of ANK (ANKH) may have a separate function (other 
than PPi transport) [15]. 
 Several ANKH gene mutations in CMD patients have been reported in the 
literature.  Most mutations occur on exons 7-10 of the gene [55, 62].  A list of so far 
discovered mutations in ANKH resulting in the AD form of CMD is shown in Table 1.   
 
  
	14 
Table 1: Genetic mutations of ANKH protein resulting in CMD. 
Tabulated below is a list of all genetic mutations in ANKH currently known to result in 
the development of AD-CMD.  Additionally listed is a mutation in connexin 43, which 
has been documented as being a causing factor for the development of AR-CMD. 
* The mutation in connexin 43 (gap junction protein, alpha-1) is associated with the 
autosomal dominant form of CMD [33]. 
 
Location DNA change Amino Acid change 
Reference 
Exon 7 
c.853-870del p.V285_Y290del [20] 
c. 936T>C, c.938C>G, 
c.942_953del 
p.Y290Q, W292-E295del 
[88] 
c.942T>C p.W292R [55] 
Exon 8 
c.1059T>C p.C331R [55] 
c.1001T>G p.L334R [45] 
Exon 9 
c.1015T>C p.C339R [45] 
c.1192_1194delCCT p.S375del [55, 62] 
c.1127_1129delTCT p.F376del [62] 
c.1196_1198 del CTT p.F377del [55, 62] 
Intron 9 c.1210-4 A>G p.380_V381insAla [55] 
Exon 10 
c.1139_1141insCAG p.380insA [55, 62] 
c.1233G>A p.G389R [55] 
c.1172T>C p.L391P [45] 
c.1178-1189del p.T393K396 [20] 
Connexin 
43* 
c.716G>A p.R239Q [33] 
 
 Presence of any one of the autosomal dominant genetic mutations will confirm the 
inheritance of CMD from parent to child.  Another importance of referencing the HGMD 
when conducting genetic analysis is to help distinguish AD vs. AR forms of CMD.  Due 
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to the variety of phenotypes presented in CMD patients, it is not obviously clear which 
form of CMD a patient may display, by clinical observation alone.   
 The AR form of CMD has been mapped to chromosome 6q21-2 [36].  Mutations 
in the connexin 43 gene (Cx43) have been identified as a causative factor in AR-CMD 
development [33].  Cx43 codes the gene product for protein gap junction alpha-1 (GJA1) 
[33]. 
 To inherit AR-CMD, both parents must carry a mutated recessive gene, and there 
is a resulting 25% chance of inheritance to the offspring.  The presence of an AR form of 
CMD is an even more rare find than AD-CMD and contains a variation of severity of 
clinical manifestations.  An important distinction between AD and AR forms of the 
disease, is that the disease is apparent only if both alleles carry causative variants while 
heterozygous offspring appear physically normal. In contrast, AD-CMD has a 50% 
chance to be passed on the next generation and a mutation in a single allele is sufficient 
to cause the disease [55, 62]. 
 Recently, there has been a novel discovery in the genetics of AR-CMD.  A 
mutation in the C-terminus of GJA1 coding for connexin 43 (Cx43) has been discovered 
in 6 subjects of 3 different families, resulting in AR-CMD [33].  Separate mutations 
within Cx43 are known to result in at least 7 other bone disorders, which indicates that 
connexin 43 plays an important role during skeletal development and bone maintenance 
[33]. 
 The third and final way CMD can be acquired in an individual is through 
spontaneous genetic mutation [88].  Somatic mutations have not yet been described in 
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CMD patients. It appears that mutations occur early during development and affect the 
germline therefore they can be transmitted to the next generation. DNA testing for CMD 
has been performed from both saliva and blood, suggesting that de novo mutations may 
affect the germline. 
 Historic literature reporting on CMD patients diagnosed through clinical 
presentation, generally do not contain genotyping data.  Since genotyping is not included, 
there is no concrete way to determine that the patients carried CMD specifically, opposed 
to a separate but similar bone remodeling disorder.  Careful consideration must be used 
when examining the historic literature of CMD, due to the lack of provided genetic 
evidence. 
 Currently, the biochemical and genetic foundation behind craniometaphyseal 
dysplasia is currently not completely understood.  This is due partially to the rarity of the 
disease – with over 100 cases mentioning “craniometaphyseal” or “cranio-metaphyseal” 
in the literature cataloged in Pubmed/Pubmed Central [48].  No epidemiological data is 
currently available, however estimating from the published literature we can assume there 
are only a few thousand patients worldwide. 
 
Treatment options 
The age of patients from the literature diagnosed with CMD have ranged from 
infancy to adulthood.  With diagnosis occurring at different ages, physicians detect the 
disease at varying levels of severity and disease progression.  Thus, treatment options 
must be catered specifically to each patient based on: the severity of disease within the 
	17 
patient, the patient’s age, how each patient’s body has specifically compensated for the 
disease, and each patient’s individual goals for disease treatment.  
Surgical treatment is often suggested to combat neurological issues caused as a 
result of CMD.  Commonly reported procedures include enlarging cranial foramina to 
decrease compression on affected cranial nerves and vasculature penetrating through the 
cranium [38].  One example is enlarging the foramen magnum used to reduce pressure on 
the brainstem, used for CMD patients with comorbid Chiari I malformation.  Most 
surgical procedures, to assuage pressure on nerves and vasculature passing through 
cranial foramen, are conducted via an extracranial route.  This extracranial approach is 
generally taken due to difficulty penetrating the abnormally thickened skull tissue seen in 
CMD patients.  The abnormal skull tissue can reach diameters of 50mm or more, 
compared to the 6-7mm thickness of skull tissue found in normal physiology [38].  Even 
in extracranial procedures, surgical intervention may become difficult due to the 
increased hardness of patient skulls, causing resulting abrasion of surgical instruments.  
An option available to some patients is to reduce the skull thickness to within the 
normal physiological range via a reduction cranioplasty.  Whether or not a patient can 
undergo this procedure varies, and the decision is made at the craniofacial surgeon’s 
discretion.  Patients suffering from CMD do not contain a homogenous density within 
their craniofacial bones, as found in normal physiology [38].  This means surgeons 
cannot take a simple approach to reduce the skull thickness consistently from the outside 
in, to a desired depth.  Choosing to undergo reduction cranioplasty includes life-
threatening risks, such as passing through the skull and into the dura mater leading to 
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brain hemorrhages.  Additionally, within the thick bone often lays copious vasculature.  
Removing a significant amount of bone presents the possibility of reducing the brain’s 
blood supply through bone, thus risking the patient undergoing a potential stroke.  
Deciding whether or not to undergo a cranioplasty reduction surgery procedure varies on 
a patient-to-patient basis, where compensation for nerve and vasculature compression and 
amount of bone vasculature may vary significantly between CMD patients. 
Surgical options to assuage CMD complications are not limited to treating only 
neural deficits.  Complications with nasal breathing may also be surgically repaired.  
Through extracranial surgery, the nasal cavity may be widened, to ease patient breathing.  
This approach can help treat patients of CMD in their infant years, when nasal breathing 
may be difficult due to early hyperplasia of the nasal choanae.  Reduced nasal breathing 
is often compensated in the individual by mouth breathing, however there is a report of 
severe choanal stenosis in an infant CMD patient, resulting in cardiopulmonary arrest 
[17].  This is increasingly important in neonates, since the epiglottis and soft palate are 
close to the tongue, thus reducing compensatory mouth breathing, and increasing risk of 
asphyxia if choanal atresia is severe enough [17]. 
Mandibular prognathism is another common facial disfiguration caused by CMD, 
where the mandible can be overgrown and extend further ventral than the maxilla.  
Surgical and hormonal corrections can be performed to change facial aesthetics by 
skeletal contouring [46].  This procedure includes high doses of calcitonin initially to 
inhibit bone formation, and later high doses of calcitriol to induce an increase in bone 
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resorption [46].  This attempt of a hormonal calicitonin/ calcitriol treatment, did not lead 
to any significant positive result in the patient. 
Many patients suffering from hydrocephalus as a result of CMD have been 
successfully treated as well.  Hydrocephalus is a condition in which there is an increased 
intracranial pressure (ICP) due to an abnormal amount of CSF buildup in the ventricles of 
the brain.  Hydrocephalus and ventriculomegaly are often treated with surgical 
intervention.  In severe cases, immediate cannulation and draining of CSF from the 
ventricles can rapidly reduce pressure on the brain and brainstem.  Often times the 
accumulation of CSF will subsequently return, thus a more permanent solution includes 
implanting a surgical shunt to drain the CSF from skull, into the abdominal cavity [64]. 
With the dominance of surgical intervention, various non-surgical interventions 
are much less popular as supplemental or independent treatment options for CMD 
patients.  Hormonal treatment regiments include calcitonin therapy and calcitriol 
treatment with a low calcium diet [46].  Calcitonin therapy acts to suppress osteoclasts, 
thus inhibiting osteoblast bone formation through the RANK/RANK-L feedback system. 
Studies contradict this approach due to abnormal osteoclast formation and functioning 
[15].  Thus inhibiting osteoclasts by calcitonin therapy, may have unwarranted 
detrimental effects.  
Calcitriol (1,25-dihydroxyvitamin D3) treatment includes an additional lifestyle 
change of introducing and maintaining a low calcium diet, in addition to hormonal 
therapy.  The low calcium diet will promote hypocalcemia, thus inhibiting osteoclast 
activation from monocyte precursors.  The low calcium diet works alongside calcitriol 
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induced increases in bone resorption, to slow the progression of excess bone formation.  
This approach has been reported to delay the progression of skull ossification in two 
cases of infant female patients [40, 63].  The efficacy of this method is questionable, due 
to the vast variation of phenotype progression in CMD patients.  Larger studies would be 
needed to show hormonal therapy’s efficacy in comparison to the more predominantly 
used surgical intervention for palliative treatment of CMD patients. 
As with surgical intervention, due to the wide range of phenotypic variation 
between CMD patients, whether or not to undergo hormonal therapy should be made 
based on a patient-to-patient basis.  Considerations include factors such as delayed 
dentition, bone strength, composition and density, and baseline hormone levels [67]. 
Comparatively, surgical decompression is more effective than hormonal 
approaches in improving neurological deficits resulting from bony overgrowth in the 
cranial foramen of CMD patients.  Surgical removal of bony overgrowth within the 
cranial foramen will begin decompression of the cranial nerves, reducing the regression 
of their sensory content.  Removing parts of the skull bone to reduce pressure on the 
brainstem and spinal cord, as well as increasing space available for the cerebellum has 
been shown to increase sensory perception and motor function within patients as quickly 
as 6 weeks post-surgery [66]. 
While surgical intervention and hormonal therapy have been discussed, 
overlooked supplements to these approaches, are the various types of physical and 
occupational therapies available.  Physical therapy can help to stimulate facial muscles in 
cases of facial nerve palsy secondary to CMD.  Additionally, physical therapy can help 
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improve motor function of extremities, which may be reduced due to sclerosis of the 
skull base cranial foramina [20].  Present in many CMD patients, are concurrent 
debilitation in sensory responses and motor function.  Occupational therapy can allow 
some subjects with CMD to develop lifestyle adaptations to compensate for debilities 
caused by the disease, increasing their quality of life.  This includes therapies for coping 
with blindness and deafness, which can be secondary effects of CMD [3]. 
Currently, no treatment or combination of treatments for CMD has been indicated 
curative.  Patients are only offered palliative solutions to help reduce the physiological 
impact of CMD, and occupational therapy to help accommodate for the lifestyle 
difficulties that CMD patients face.   
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SPECIFIC AIMS 
 
 The overall objective of this report is to compile and organize the known 
information on craniometaphyseal dysplasia, in order to conduct a natural history of 
disease pilot study of the rare skeletal bone disease, CMD.  Doing so will set a precedent 
for understanding the foundation and progression of CMD, and relay this information to 
research groups interested in conducting a full scale natural history study of CMD.   
 To compile the information necessary to conduct a pilot study, and direct a future 
natural history of disease study, this project is designed through the accomplishments of 
three specific aims: 	
SPECIFIC AIM 1:  Compile an organized collection of publications to use as a 
starting point for a natural history study for CMD. 
 In the current literature, there is no single definitive study investigating the 
etiology, clinical manifestations, and timeline of progression of the disease.  
Additionally, there are no reports compiling the information from a large number of 
CMD cases.  Our current understanding of CMD relies on publications based on cases.  
Different studies investigate different parameters of the disorder, making it hard to 
directly compare phenotypic progression of CMD.  This study seeks to streamline the 
presentation of information on CMD, through the presentation of a compendium of 
publications pertaining to specific characteristics of the disease.  In doing so, future 
groups seeking to learn more about CMD may refer to this compendium for guidance on 
where to look for information. 
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SPECIFIC AIM 2:  Assess the available data on the CMD patient population 
available in the Reichenberger Lab, to determine what clinical information is 
already available. 
 Currently, a patient population of CMD subjects with information of genetic 
mutations and clinical data for individual cases is available in the Reichenberger Lab at 
University of Connecticut Health (UCH) in Farmington, CT (unpublished).  Genetic data, 
along with the existing clinical data are assembled in a database.  Clinical correlations are 
made through comparison of compiled data.  Understanding what clinical information is 
already available within the database of CMD patient cases at the Reichenberger Lab is 
crucial for later deciding which clinical qualities will be of most interest for further 
investigation.  Additionally, cataloging information is already present will help determine 
what additional information remains to be collected from these existing patients, when 
planning for a larger scale natural history of disease study for CMD. 
 
SPECIFIC AIM 3:  Analyze existing collected clinical data to determine which 
parameters may be of interest for further investigation in a large scale natural 
history study of CMD. 
 Once the CMD patient population data within the Reichenberger Lab at UCH has 
been examined to determine which pertinent recorded clinical information is available for 
each patient, clinical information will be analyzed.  It is important to understand any 
preexisting trends in the data, as they will help to set a foundation for what information 
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should be focused on for collection in a future full scale CMD natural history of disease 
study Additionally, clinical data published in the literature may also be used in 
comparison with the subjects from the Reichenberger Lab CMD patient database, for 
analyzing trends. 
 
 Between the literature, and the CMD patient population database at the 
Reichenberger Lab, these three aims seek to discover what information on CMD is 
currently available, and how this information can be incorporated in directing a future 
natural history of disease study for CMD.  Research groups interested in further 
developing a full scale natural history of disease study for CMD will be able to use the 
work from this project as a roadmap. 
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METHODS 
 
SPECIFIC AIM 1:  Compile an organized collection of publications to use as a 
starting point for a natural history study for CMD. 
 For this project, the literature was sorted and subsequently organized into succinct 
categories containing information specific to individual characteristics of the disease.  
Publications were collected by searching for “craniometaphyseal,” or “craniometa-
physeal,” within the PubMed and PubMed Central databases.  Despite over 120 
publications returned from the search, the database only provided links to online copies 
of original publications for roughly 90 of the reported studies of CMD.  The publications 
able to be collected directly from PubMed/PubMed Central were used in this study, as 
these are the publications that can be publically found by future research groups seeking 
to further investigate CMD.  The remaining publications are most likely only available in 
print or through intralibrary loans.  These publications were not included due to regional 
limitation, along with the temporal restraints placed on completing this thesis. 
  The literature was grouped to provide a basis for researchers to understand: the 
diagnosis, known biochemistry, and genetic basis of CMD.  In doing so, eight major 
categories of published research were organized for presentation to the general public 
interested in learning more of CMD: 
1. Genetic mutations resulting in CMD 
2. Molecular mechanisms of CMD 
3. CMD case reports 
4. CMD differential diagnosis 
5. Surgical & medical therapy for CMD 
6. 2º Abnormalities resulting from CMD 
	26 
7. Familial studies of CMD 
8. CMD overview and literature review 
 
The categories of publication groups are defined to help address the key information 
necessary in understanding CMD.  Understanding these foundations of CMD individually 
is critical to gain a gestalt understanding of the disease.  Additionally, in categorizing the 
literature into groups, publications with outdated information or possibly incorrect 
information can be more easily identified. Progressing within a specific category of 
papers in chronological order, one may find a publication with a novel discovery 
contradicting and outdating the discoveries of a previous paper. 
Since the disease is not well known, all publications found on CMD during this study 
were included in the research compendium.  In doing so, any research group interested in 
further investigating CMD can make their own autonomous conclusions regarding which 
studies provide beneficial information, and publications for which the information has 
been outdated. 
 
SPECIFIC AIM 2:  Assess the available data on the CMD patient population 
available in the Reichenberger Lab, to determine what clinical information is 
already available. 
 The CMD patient population collected so far at the Reichenberger Lab at UCH 
exists of 76 different cases, collected previously for studies relating to the underlying 
genetic basis of CMD.  Though many of the case files within the CMD patient database 
at the Reichenberger Lab were generated with the goal of determining genetic mutations 
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leading to the disease, clinical information is present as well, however, scarce and 
variable for many cases. 
 Within the clinical information available in the subject database, availability of 
the data varies between subjects.  The available clinical information for each of the 
individual cases has been listed, with attention towards clinical parameters deemed 
important by their relativity of occurrences in previously published CMD studies.  This is 
valuable in creating an inventory of clinical data already available within the CMD 
patient database, thus identifying which information still needs to be collected from these 
patients if they are to be a part of a future natural history of disease study of CMD. 
 All cases in the CMD patient database, were individually determined as to 
whether or not they contain information for the following parameters:  
1. Patient Information 
2. Referring Physician Contact Information 
3. Tissue Sample (available) 
4. Blood Chemistry (some) 
5. Growth Information 
6. Skull Diameter Measurements 
7. Visual Acuity 
8. Auditory Acuity 
9. Clinical Symptoms 
10. Radiological Data 
11. Surgical and or Hormonal Treatment Information 
12. ANKH Mutation Present 
13. Connexin 43 Present 
14. Diet and Exercise Information 
 
 To avoid incorporating data from patients with other skeletal disorders that aren’t 
CMD, only patients with known mutations resulting in CMD (mutations in ANKH and 
connexin 43) are included in this study.  Patients not identified as having mutations in 
ANKH or Cx43 are disregarded for this pilot study, as they may possibly have a bone 
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disorder with similar clinical manifestations or mutations outside the exons that were 
sequenced for the study.  Though reducing population size for inclusion in a future 
natural history of disease study for CMD, these exclusions increases precision of the 
study, by reducing confounding information from patients with other potential non-CMD 
skeletal disorders.   
 Personal health information is de-identified in all tables and database files for this 
study.  Identifiable information is kept under lock in the Reichenberger Lab at UCH as 
per approved IRB protocol. 
 
SPECIFIC AIM 3:  Analyze existing collected clinical data to determine which 
parameters may be of interest for further investigation in a large scale natural 
history study of CMD. 
 To evaluate trends within data of the CMD database the inventory created from 
the second aim was used to identify the subject cases containing the most available and 
relevant clinical data. 
 Two patients with detailed clinical data available were used as examples of 
comparison for this proposed analysis.  Details of the two patient cases are shown below 
in Table 2 [Reichenberger, unpublished].  
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Table 2: Demographic information of two patient cases used for comparison in pilot 
CMD natural history of disease study. [Reichenberger, unpublished]. 
The two cases were chosen such that a comparison of disease progression could be made 
from 2003 onwards in two CMD patients of: similar age 
 
 CASE 1 CASE 2 
Sex Female Male 
Year of Birth 2003 2003 
Mutation (in ANKH) p.Ser375del p.Phe376del 
Race Asian Whitej 
 
 These two cases were chosen on the basis that they contain the most information 
available in the CMD database and are of similar age.  Using these two subjects for 
comparison, allows clinical changes and disease progression over time to be compared 
more accurately as it removes the confounding variables associated with the changes in 
disease progression over age. 
 Using the two cases, varying quantitative and qualitative clinical measurements 
and clinical observations were compared.  The comparisons were made both amongst the 
two CMD patient cases, as well as alongside the baseline clinical measurements and 
clinical observations of a non-disease standard.  Clinical parameters chosen for analysis 
were based on the clinical measurements commonly used in identified CMD publications.  
This ranged from qualitative measurements such as changes in bone hypertrophy between 
yearly checkups, to quantitative measurements of blood chemistry.  The results from 
these comparisons in association with the clinical measurements reported in the literature 
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were ultimately used to compile a list of pertinent clinical parameters for further 
investigation in future studies of CMD. 
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RESULTS 
 
SPECIFIC AIM 1:  Compile an organized collection of publications to use as a 
starting point for a natural history study for CMD. 
After analyzing the available CMD literature, important publications were compiled and 
categorized within eight main categories: 
1. Genetic mutations resulting in CMD 
2. Molecular mechanisms of CMD 
3. CMD patient case reports 
4. CMD differential diagnosis 
5. Surgical & medical therapy for CMD 
6. Secondary phenotype resulting from CMD 
7. Familial studies of CMD 
8. CMD overview and literature review 
 
These publications are sorted and organized below in Table 3.  All publications listed 
below were obtained via PubMed/PubMed Central.  Some of the older publications on 
CMD were listed, however, only publications that were electronically available were 
obtained. 
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Table 3A:  Categorized published literature on craniometaphyseal dysplasia.  
A:  Genetic mutations resulting in CMD & molecular mechanisms of CMD. 
All publications cited in Table 3 are reduced to only cite the primary author and year.  
The full citations of these publications are detailed in the bibliography 
 
Genetic mutations resulting in CMD 
 
1. Chen et al., 2013 [12] 
2. Hu et al., 2013 [33] 
3. Kato et al., 2013 [39] 
4. Dutra et al., 2012 [21] 
5. Huang et al., 2011 [34] 
6. Protera et al., 2011 [59] 
7. Chen et al., 2011 [15] 
8. Kornak et al., 2010 [45] 
9. Zajac et al., 2010 [88] 
10. Chen et al., 2009 [14] 
11. Wang et al., 2009 [79] 
12. Reichenberger et al., 2001 [62] 
13. Nurnberg et al., 2001 [55] 
14. Chandler et al., 2001 [10] 
15. Iughetti et al., 2000 [36] 
16. Nurnberg et al., 1997 [56] 
17. Reichenberger et al., 1993 [61] 
Molecular mechanisms of CMD 
 
1. Stains & Civitelli, 2015 [70] 
2. Chen et al., 2014 [11] 
3. Chen et al., 2013 [12] 
4. Las Heras et al., 2012 [47] 
5. Moochhala, 2012 [50] 
6. Zhao et al., 2012 [89] 
7. Chen et al., 2011 [15] 
8. Collins et al., 2011 [18] 
9. Xu et al., 2011 [84] 
10. Kim et al., 2010 [41] 
11. Neunaber et al., 2010 [54] 
12. Oca et al., 2010 [57] 
13. Skubutyte et al., 2010 [69] 
14. Carr et al., 2009 [9] 
15. Chen et al., 2009 [14] 
16. Kirsch et al., 2009 [44] 
17. Wang et al., 2009 [79] 
18. Moochhala et al., 2008 [51] 
19. Wang et al., 2008 [78] 
20. Wang et al., 2007 [80] 
21. Gurley et al., 2006 [29] 
22. Wang et al., 2005 [81] 
23. Pendleton et al., 2002 [58] 
24. Guo et al., 2001 [28] 
25. Yamamato et al., 1993 [85] 	 	
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Table 3B:  Categorized published literature on craniometaphyseal dysplasia.  
B:  CMD patient case reports, CMD differential diagnosis, surgical & medical 
therapy for CMD, and 2º Abnormalities resulting from CMD. 
All publications cited in Table 3 are reduced to only cite the primary author and year.  
The full citations of these publications are detailed in the bibliography. 
 
CMD patient case reports 
 
1. Taggart et al., 2014 [72] 
2. Esteves et al., 2014 
3. Tanigawa et al., 2011 [74] 
4. Rivero-Garvia et al., 2011 [64] 
5. Lamazza et al., 2009 [46] 
6. Vasu et al., 2006 [77] 
7. Kim et al., 2005 [43] 
8. Shepard et al., 2003 [67] 
9. McKay & Filov, 2002 [48] 
10. Feingold et al., 1999 [26] 
11. Boltshauser et al., 1996 [5] 
12. Hudgins et al., 1987 [35] 
13. Nema et al., 1974 [53] 
14. Carlson & Harris, 1972 [8] 
CMD differential diagnosis 
 
1. Chen et al., 2014 [11] 
2. Waterval et al., 2014 [82] 
3. Lamezza et al., 2009 [29] 
4. Faden et al., 2009 [24] 
5. Baynam et. al., 2009 [2] 
6. Cai et al., 2008 [7] 
7. Richards et al., 1996 [63] 
8. Beighton, 1995 [3] 
9. Reichenberger et al., 1993 [61] 
10. Reardon et al., 1991 [60] 
11. Gorlin et al., 1969 [27] 
12. Jackson et al., 1954 [37] 
Surgical & medical therapy for CMD 
 
1. Twigg et al., 2015 [76] 
2. Kim et al., 2013 [42] 
3. Rivero-Garvia et al., 2011 [64] 
4. Juergens et al., 2011 [38] 
5. Sewell, 2008 [66] 
6. Singhal, 2008 [68] 
7. Ahmed et al., 2006 [1] 
8. Kim et al., 2005 [43] 
9. Shepard et al., 2003 [67] 
10. Day et al., 1997 [20] 
11. Cheung et al., 1997 [16] 
12. Satoh et al., 1994 [65] 
13. Fanconi et al., 1988 [25] 
14. Key et al., 1988 [40] 
2º Abnormalities resulting from 
CMD 
 
1. Chen et al., 2014 [13] 
2. Dutra et al., 2013 [22] 
3. Tanaka et al., 2013 [73] 
4. Chida et al., 2011 [17] 
5. Collins et al., 2011 [18] 
6. Sun et al., 2011 [71] 
7. Singhal, 2008 [68] 
8. Sewell, 2008 [66] 
9. Cai et al., 2008 [7] 
10. Vasu et al., 2006 [77] 
11. Mintz & Veliz, 2004 [49] 
12. Pendleton et al., 2002 [58] 
13. Hayashibara et al., 2000 [31] 
14. Elcioglu & Hall, 1998 [23] 
15. Boltshauser et al., 1996 [5] 
16. Haverkamp et al., 1996 [30] 
17. Fanconi et al., 1988 [25] 
18. Hudgins et al., 1987 [35] 
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Table 3C:  Categorized published literature on craniometaphyseal dysplasia.  
C:  Familial studies of CMD & CMD overview & Literature review. All	publications	cited	in	Table	3	are	reduced	to	only	cite	the	primary	author	and	year.		The	full	citations	of	these	publications	are	detailed	in	the	bibliography,	correlated	to	their	citation.		
Familial studies of CMD 
 
1. Hu et al., 2013 [33] 
2. Kato et al., 2013 [39] 
3. Protera et al., 2011 [59] 
4. Morava et al., 2011 [52] 
5. Baynam et. al., 2009 [2] 
6. Pendleton et al., 2002 [58] 
7. Iughetti et al., 2000 [36] 
8. Tinschert & Braun, 1998 [75] 
9. Nurnberg et al., 1997 [56] 
10. Beighton et al., 1995 [3] 
11. Beighton et al., 1979 [4] 
12. Carlson & Harris, 1972 [8] 
CMD overview & literature review 
 
1. Chen et al., 2014 [11] 
2. Waterval et al., 2014 [82] 
3. Cai et al., 2008 [7] 
4. Shepard et al., 2003 [67] 
5. Reichenberger et al., 1993 [61] 
6. Brueton et al., 1990 [6] 
7. Cooper et al., 1974 [19] 
 
 
SPECIFIC AIM 2:  Assess the available data on the CMD patient population 
available in the Reichenberger Lab, to determine what clinical information is 
already available. 
Of the available patients in the CMD patient database at the Reichenberger Lab at 
UCH, a total of 76 individual patient cases were found eligible for consideration for 
incorporation in a future natural history of disease study, through confirmation of a 
sequenced ANKH or CX43 mutation.  Since mutations in these genes are the only known 
mutations in the literature and the Human Gene Mutation Database (HGMD) identified to 
result in CMD development, patients with similar clinical symptoms but without genetic 
confirmation were excluded.  This was done to avoid enrolling patients who may have 
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clinical symptoms similar to CMD, but a differential diagnosis of a non-CMD bone 
disorder. 
Of the 76 patient cases, each case was scrutinized for clinical information 
ascertained during a previous genetic study.  A survey of available pre-existing clinical 
information within the CMD patient database is displayed in Table 4. 
 
Table 4: Clinical information present in case files within the CMD Database at the 
Reichenberger Lab at University of Connecticut Health. 
The clinical information for identification was determined on the basis of what was most 
commonly investigated and reported in the previously published CMD literature. 
 
Clinical Parameters of Interest Patients 
 
Patient Information 
26 
Referring Physician Contact Information 54 
Tissue Sample (available) 7 
Blood Chemistry (some) 4 
Growth Information 6 
Skull Diameter Measurements 6 
Visual Acuity 5 
Auditory Acuity 6 
Clinical Symptoms 10 
Radiological Data 11 
Surgery and/or Hormonal Treatment 
Information 
10 
ANKH Mutation Present 65 
Connexin 43 Mutation Present 11 
Diet & Exercise Information 1 
Total Patient Cases Considered 76 
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Within these categories, the available information varies by each patient.  No case 
contains a full set of clinical data spanning over the subject’s lifespan.  Available 
information was also found to be dependent on the varying documentation styles of 
different physicians, and which clinical tests were conducted for each patient.  After 
documenting the clinical information present within the database, two cases (Table 3) 
were determined suitable for comparison in this pilot study. 
 
SPECIFIC AIM 3:  Analyze existing collected clinical data to determine which 
parameters may be of interest for further investigation in a large scale natural 
history study of CMD. 
 
Case 1 
  Case 1 is a 13 year old girl with CMD.  She was born to two healthy 
nonconsanguinous parents of Asian descent.  In 2003, she was delivered vaginally with a 
nuchal cord complication, and was noted as hypovolemic shortly after birth.  The subject 
was immediately resuscitated via bag and mask ventilation and transferred to the ICU to 
normal recovery.  At birth, she was measured with a head circumference of 33cm (39h 
percentile,) birth weight of 2740g (27th percentile) and birth length of 48cm (42nd 
percentile).  At birth, the subject was confirmed responsive to both sight and hearing.  
The subject also was identified to exhibit mild nasal flaring during respiration 
immediately after birth, and identified as anemic, though hemodynamically stable upon 
discharge. 
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Within the first postnatal months, the subject exhibited frontal bossing, biparietal 
widening and moderate ocular telorism and a wide flat nasal bridge.  It was noticed by 
her parents that there was blinking in one eye more than the other, and when presented to 
her PCP, pallor of the optic discs was discovered.  In her first year, CT scans confirmed 
bony sclerosis in subcortacoid space of sulci (involving skull base and calvariae) 
resembling the common trait of thickening of the skull base seen in CMD patients.  
Worsening of bone hypertrophy around the skull base and optic nerve helped to explain 
visual issues.  
 In her first year, radiographic imaging also confirmed the patient’s middle ear 
cavities obliterated by bony thickening of the otic canal and a resultant narrowed internal 
auditory canal.  As audiology tests reported decreased auditory acuity in the subject, at 
six months of age, she was given hearing aids to help improve her hearing capacity.  By 
the end of her first year, Case 1 was diagnosed with a skeletal dysplasia, though an exact 
diagnosis was decided to be made later after additional testing. 
Though not given the confirmed differential diagnosis of CMD, by age 1, physical 
therapy was provided for Case 1.  Therapy included visual stimulations to increase motor 
coordination, in conjunction with the sight of her one working eye.  Massage therapy was 
used to help stimulate facial nerves once partial CN VII paralysis was observed, to 
prevent complete facial palsy.  Humidifiers with bronchodilators were also used to help 
assuage nasal breathing, working against the bony hypertrophy of the nasal choanae.  
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In the subject’s second year after birth, she was measured with a: skull 
circumference of 53.75cm (97th percentile) weight of 35 lbs (90th percentile) and height 
of 38.25 inches (90th percentile). 
In her third year of life subarachnoid spaces over convexities and 
interhemispheric fissure were noted to be smaller than the year before, due once again to 
continued bone hypertrophy.  Additionally skull, mandible and proximal cervical spine 
were found sclerotic with diffuse marrow expansion, internal auditory canals and middle 
ear were declared stenotic, skull base foramina were narrowed and mastoid sinuses were 
found to be non-pneumatized.  All resulting symptoms were determined to be due to 
bony sclerosis.  Additional displacement of cerebellar tonsils 12mm below her foramen 
magnum, with associated pointing of tonsils and mild cervicomedullar compression, 
showed evidence of severe type 1 Chiari malformation.   
In her fourth year, interestingly, clinical reports indicated thickening of calvarium 
and facial bones had remained unchanged over the past year. Voids and dural sinuses 
were additionally noted to remain unchanged, halting the progressive compression seen 
in previous years.   
Radiographic imaging of the characteristic “Erlenmeyer Flask” shape of her 
femur was documented, displaying the possibility of an initial misdiagnosis of CDD.  At 
age 10, the subject’s blood was sent to the Reichenberger Lab, for participation in a 
genetic study.  After genetic sequencing, the patient was confirmed to contain the 
Ser375del mutation of ANKH, specific to CMD development.  
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By the fifth year, the subject underwent her first recorded vision test, with results 
of: OD 20/800 (right), OU (20/2100) (left), OS (20/800) both.  This confirmed the subject 
to be blind in her left eye, however still able to process some vision in her right eye, 
which remains her only visual support. 
Palliative therapy for Case 1 included two surgical interventions.  At age 6, a 
ventriculo-peritoneal shunt was inserted to drain excess CSF from the cranium to the 
peritoneum, helping alleviate recurring headache believed to be caused by high ICP 
resultant of the subject’s increased bone mass and reduced sinuses.  At age 10, a 
craniotomy was performed to reduce pressure from the hypertrophied skull on the 
patient’s cerebellum - pressure which had been restricting motor function of the subject’s 
upper extremities.  At the same time, a C1lamenectomy was performed to reduce 
pressure on the cerebellar tonsils pushed below the skull caused by the patient’s Chiari 1 
malformation.  Case 1 also underwent early childhood intervention, with both physical 
therapy and occupational therapy. 
In her yearly blood chemistry tests, it has been noted that Case 1 has recurrently 
had high cholesterol, which could be associated to diet or extraneous genetic factors.  
Additionally, after being released from the hospital as anemic post-birth, Case 1 has 
displayed low hemoglobin and/or hematocrit counts for 6 out of the 7 years in which her 
case has identifiable clinical blood chemistry measurements.  Additionally, the subject 
reports high BUN/Creatinine levels in 4 out of 7 years in which her case has blood 
chemistry measurements.  These observations are displayed in Table 5. 
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Table 5:  Significant blood chemistry trends seen in Case 1. 
Shown are values of the trends in blood chemistry indicated above.  Clinical blood 
chemistry values measured in the subject are reported on top, while reference range 
values are reported parenthetically below it.  Reference ranges are provided by the 
individual labs conducting the blood work exams.  
* Indicates that values were not provided in the patient’s clinical case file. 
 
Case 1 Clinical Blood Work Values of Interest 
Age 
ALP (U/L) 
(ref. 
range) 
BUN/Creatinine 
(ref. range) 
Hemoglobin 
(g/dL) 
(ref. range) 
Hematocrit (%) 
(ref. range) 
0 1107 (40-350) * 
13.2 
(12.8-20.4) 
39.1 
(50-76) 
1 1338 (25-500) 
63 
(8-27) 
11.4 
(10-14) 
32.7 
(30-42) 
2 705 (100-400) 
40 
(8-27) 
12.3 
(10-14) 
36 
(30-42) 
3 482 (100-400) 
38 
(8-27) 
11.9 
(11.2-14.3) 
34.9 
(32-44) 
4 468 (96-297) 
48 
(6-22) 
11.9 
(11.5- 14.0) 
34.7 
(34-42) 
5 303 (93-309) 
47 
(6-22) 
11.6 
(11.7-15.5) 
32.9 
(35-45) 
6 330 (96-297) 
43 
(6-22) 
11.6 
(11.7- 15.5) 
32.9 
(35-45) 
7 351 (184-415) 
normal 
(*) 
12.7 
(11.5-15.5) 
37.7 
(35-45) 
8 427 (100-400) 
30 
(9-25) 
12.6 
(11.7-15) 
38.5 
(34.8-43.5) 
9 316 (100-400) 
28 
(9-25) 
11.7 
(11.7- 15.7) 
38.1 
(34.8-45.8) 
10 434 (104-471) 
24 
(9-25) 
11.6 
(11.5- 15.5) 
36.3 
(35-45) 
11 306 (104-471) 
* 
(6-22) 
11.9 
(11.7- 15.7) 
36.3 
(34.8-45.8) 
12 227 (134-439) 
24 
(9-25) 
9.9 
(11.7- 15.7) 
32.8 
(34.8-45.8) 
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The subject has been described as a friendly, very social, and helpful and 
intelligent child.  At the age of 5 she was shown to have oral comprehension skills at a 
third grade level.  The subject’s lifestyle includes dietary restrictions of beef and pork for 
religious reasons.  She enjoys drinking two cups of tea (with milk) a day.  Of normal 
intelligence, she currently attends the New York Institute for the Blind and participates in 
school social activities and exercise during physical education.  Her main communication 
is through speech and is taught in both print and braille.  The subject has minimal 
exercise outside of school, only on long walks running errands or doing family activities 
at local parks. 
 
Case 2 
Case 2 is a 12 year old boy born to two nonconsanguinous parents in 2003. 
Shortly after birth, it was noted the subject had thick effusion in middle ear, no air space 
in the right tympanic membrane and an eardrum and incus overlap in right ear.  In his 
first year after birth, he has been reported to often catch a cold (presents stuffy nose). 
 In the subject’s second year, he presented with sclerosis of the calvarium, and a 
dense sclerosis of the skull base (much more dense than that around the calvarium).  The 
subject also displayed sclerotic ribs but an unaffected vertebrae.  The nasal choanae were 
shown to be obstructed.  Despite the vertebrae not being affected by bony overgrowth, in 
radiographic images there was confirmed sclerosis and thickening in the shaft of the 
patient’s long bones.  Along with the constant stuffy nose, telecanthus was observed, 
leading to increased excretion from the subject’s tear ducts, though pupils were shown to 
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be normal.  To ameliorate the effect, bilateral nasolacrimal duct intubation was 
introduced to help clear the tear ducts. 
 Additionally in the second year CT scans were important in displaying an 
increased skull thickness and skull sclerosis.  There was no intracranial calcification and 
coronal and sagittal sutures were not completely fused.  Paranasal sinuses were described 
as being hypoplastic.  Internal auditory canal shape was shown to be within the normal 
range, however similarly to case 1, there was hypoplasia of mastoids and paranasal 
sinuses.  Finally in Case 2’s second year, bilateral to moderate hearing loss was found 
with no response to 70 dB in each ear. 
 By Case 2’s second year, an additional 40 dB hearing loss was found in the 
subject’s right ear. Facial morphology had evolved into significant hypertelorism.  In 
contrast to Case 1’s childhood development involving more speech communication.  
Case 2 was taught sign language.  By Case 2’s second year, he was able to comprehend 
30-40 known words, and able to replicate back 5-10 words.  In terms of diet and exercise, 
Case 2 was a picky eater as a child and exercise was not significant.   
By the age of 3, Case 2’s progression of clinical manifestations of CMD seemed 
to be steadily increasing.  Right temporal bone overgrowth and right side bony 
overgrowth encroaching into the small internal auditory canal results in a 40dB loss in his 
right ear.  Nasal cavity constriction and Class 2 occlusion with an open bite was also 
reported, common to Case 1. 
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In Case 2’s 4th year, initial signs of a Chiari I malformation were found.  
Additionally, the subject’s calvariae became homogeneous in density of trabecular bone 
compared to 2006 where there was reported to be a more “ground-glass density”.   
The 5th year, however, the signs of a Chiari I malformation had increased, with 
the cerebellar tonsils being 4mm below the foramen magnum, still less than Case 1 had 
shown, with her Chiari I malformation in her third year. 
During the patient’s 10th year, it appeared that his thickening of both the 
calvarium and the optic canals have stabilized, thus in the subject’s 9th year, there was no 
acute intracranial pressure leading to damage – unlike Case 1 who needed the 
ventriculoperitoneal shunt to alleviate increased ICP.  Similar to Case 1, the patient’s 
paranasal sinuses are filled in due to expansile bony hypertrophy. 
In the 13th and final year of patient’s recorded clinical data (2015), the calvarial 
and facial structures have stopped changing significantly.  The mastoid air cells appear 
abnormal, normal inner ear anatomy and internal auditory canal remained the same, 
middle ear cavities overlap and are not well delineated.  Cerebellar tonsils also stopped 
encroaching downwards below the foramen magnum at 4mm.  Additionally, the primary 
care physician identified no definitive change in bone morphology from 2014, and 
according to the audiologist there was no change in hearing from 2014. 
 
Blood Chemistry Comparison	
 When comparing the clinical data between the two cases.  A trend was noticed 
within the blood work.  Compared to standard blood hormone levels normalized for sex 
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and age, both patients exhibited high serum alkaline phosphatase (ALP) content during 
early childhood.  While still abnormally high, the variance between the subject serum 
alkaline phosphatase level and the standardized serum alkaline phosphatase level 
decreased over time.  Serum alkaline phosphatase levels are shown in Figure 4. 
 
Figure 4: Serum alkaline phosphatase levels in both cases over time 
Reference values for normal ranges of serum alkaline phosphatase are provided by the 
laboratories responsible for each blood test.  Normal reference values for male subjects 
fall within the dashed lines, while normal reference values for female subjects fall within 
the solid lines.  For years in which there was no recorded blood work on file for each of 
the two cases, reference values supplied by the Mayo Clinic are being used. 
Note: Global reference values supplied by the Mayo Clinic are established for subjects 
over 4 years (see Appendix).  For under 4 years, reference values are provided by the 
laboratory conducting the blood work tests. 
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Despite there not being birth data for Case 2, for Case 1, clinical measurements of 
alkaline phosphatase isoenzymes were reported.  These concentrations are reported in 
Figure 5. 
 
Figure 5: Alkaline phosphatase isoenzyme levels present at birth. 
Clinical data indicating the alkaline phosphatase isoenzyme levels present at birth was 
collected for the patient in Case 1.  The concentration of bone alkaline phosphatase is 
shown to be almost three times more than the maximum reference value for bone alkaline 
phosphatase at birth. 
 
High serum alkaline phosphatase levels in CMD patients have also been indicated 
in the literature.  In one study of a 3-year-old male alkaline phosphatase levels were 1138 
IU/L, compared to the normal control range of 115-391 IU/L [85].  A table of CMD 
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patients with reported serum alkaline phosphatase levels from the literature is shown 
below (Table 6). 
 
Table 6:  Serum alkaline phosphatase levels in CMD patients as found in the 
literature. 
Historically reported serum alkaline phosphatase levels are tabulated below.  In most 
CMD cases, the serum alkaline phosphatase (ALP) levels are either elevated, or within 
the upper region of the reference rage. 
* Indicates value not provided in the publication 
Age 
(years) 
Sex Recorded ALP 
(U/L) 
ALP normal 
reference range 
(U/L) 
Notes Referenc
e 
1 Male 2417-3002 58-400 Elevated [83] 
3 Male * * Normal [33] 
4 Female 392 (IU/L) * Elevated [42] 
25 Female 51.1 * * [73] 
1-2 Female 427-1944 150-400 Elevated [21] 
<1 
(7 mo.) 
Female 4168 (IU/L) * Elevated [17] 
6 Male 533 (IU/L) 125-410 (IU/L) Elevated [45] 
36 Male * * Normal [46] 
45 Male * * Normal [49] 
<1 
(4 wk.) 
Female 1839 117-390 Elevated [67] 
2 Female 559 * Elevated [63] 
3 Male 1138 115-391 Elevated [85] 
 
 Not enough clinical data was found within the Case 2 clinical file to compare 
BUN/creatinine measurements with that of Case 1.  An interesting trend was noticed in 
an elevation of BUN/creatinine, first recorded at age 1, which gradually decreased with 
age, despite still being higher than the referred range.  This is tabulated in Table 5, 
however a visual representation is also provided in Figure 6. 
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Figure 6:  BUN/Creatinine measurements in Case 1 during childhood years. 
Shown above are the recorded BUN/Creatinine calculated values for the female patient, 
throughout her childhood years.  In all but two measurements, the BUN/Creatinine level 
is higher than the reference range values, with two measurements falling in the extreme 
high end of the reference values. 
 
Using the completion of analyzing the literature, the CMD database patient case files at 
the Reichenberger Lab at UCH, and lastly a comparison of two specific case files from 
the Reichenberger Lab CMD database, a list of clinical parameters relative to CMD 
worth further investigating was generated (Table 7). 
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Table	7:		Clinical	parameters	suggested	for	investigation	in	future	natural	
history	of	disease	studies	on	CMD.	
These variables for investigation were selected due to their considered importance in 
CMD diagnosis and disease progression. 
 
Factors for Investigation 
1 Mutation 
2 Head circumference 
3 Bone thickness 
4 Bone density 
5 Calcium 
6 Magnesium 
7 Phosphorus 
8 Alkaline phosphatase (ALP) 
9 Tartrate-resistant acid phosphatase 
10 Parathyroid hormone (PTH) 
11 Calcitonin 
12 Calcitriol (1,25-dihydroxyvitamin D3) 
13 Vitamin D 
14 Osteocalcin 
15 Osteoprogeterin (OPG) 
16 TNAP 
17 Gap junction protein alpha-1 (GJA-1) = connexin 43 (Cx43) 
18 BUN / Creatinine 
19 Caclium/creatine (urinary) 
20 Hydroxyproline (urinary) 
21 Tubular reabsorption of phosphate 
22 Auditory acuity 
23 Visual acuity 
24 Delayed primary dentition 
 
 
	49 
DISCUSSION 
Comparing two CMD patient cases 
In both subjects’ second years, clinical documentation indicates bone hyperplasia 
into the skull sinuses – mastoid sinuses in Case 1, and mastoid and paranasal sinuses in 
Case 2.  Sclerosis of the base of the skull is also indicated to be severe enough in both 
cases to result in Chiari I malformations.  Apparent reduction in bone hypertrophy of the 
calvarium also is documented to occur in both cases, however later in Case 2 (age 10) 
opposed to Case 1 (age 4). 
An additional similarity between cases is bony overgrowth within the nasal cavity 
and nasal choanae with additional Class 2 occlusion and an open bite.  These 
manifestations were both found to be congenital problems, which progressed with age.  
The hypovolemia and resultant hypoxia and need for bag resuscitation observed in Case 1 
shortly after birth, could be explained by reduced nasal breathing complicated by bony 
overgrowth within the nasal cavity.  Mild nasal flaring is listed in the respiration section 
of the subject’s birth reports possibly indicating problematic nasal breathing directly 
since birth.  Bone hyperplasia in both the nasal cavity and nasal choanae are prominent 
enough in both cases to cause both subjects to rely predominantly on mouth breathing. 
Both cases are seen by craniofacial teams to monitor and progress the changing 
bone structure in each patient as they progress with age.  Careful monitoring helps to 
detect changes in bone hypertrophy over the years, however most of the clinical 
summaries reporting the changes are qualitative and made by clinical observation.  It is 
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difficult to compare bone hypertrophy between the cases, due to the inherent bias in 
having different specialists recording the observations for each case. 
In the clinical reports, there has been significant variance of the clinical 
manifestations of CMD with age progression, between the two cases.  While Case 2 
presented sclerotic ribs and unaffected vertebrae, Case 1 differed with bony overgrowth 
within C1 severe enough to need correction by lamenectomy and minimal sclerosis of the 
ribs.   
Auditory & visual acuity variation 
 Arguably, the most significant lifestyle differences between the cases are the 
secondary effects of CMD on the auditory and visual networks within the two subjects.  
In both cases, auditory deficits are significant enough to require hearing aids.  Deficits 
appear to be most severe in the higher frequency spectrum in Case 1; however, it is 
unclear if this is replicated in Case 2.  Though bilateral hearing loss is exhibited in both 
cases, the severity of the hearing loss is indicated to vary between right and left sides in 
the clinical work of both cases.  Within individual patient cases, yearly auditory tests 
were documented as taken by different operators on different instruments between years, 
thus possibly adding a confounding variable when determining individual auditory 
changes over time. 
With a population size of only two cases for this study, it is unclear exactly as to 
the causation of variance between the clinical manifestations of the two cases.  One 
possible explanation could be that different mutations (Ser375del in Case 1, and 
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Phe377del in Case 2) play a role in the change of bone remodeling attributed to CMD.  
Variances may also be attributed to other variables such as sex, and lifestyle differences. 
 
Importance of serum alkaline phosphatase 
An important commonality found in this study, is the prevalence of high serum 
alkaline phosphatase levels within CMD patients.  Serum alkaline phosphatase is a key 
hormone in the bone remodeling process.  Serum alkaline phosphatase levels were 
determined to be abnormally high in both CMD subjects in early childhood.  While still 
remaining above or within the high spectrum of the standardized range, serum alkaline 
phosphatase levels dropped off after birth.  As this study is only a small representation of 
the CMD population necessary for a natural history of disease study for CMD, from these 
results, future studies may want to investigate serum alkaline phosphatase, calcium, 
phosphate, PPi and other blood parameter progression over time, in addition to the 
parameters mentioned in Table 7.  
Collection of data on serum alkaline phosphatase must be carefully considered, as 
there are no verified reliable reference values below 4 years of age provided by the Mayo 
Clinic (see Appendix).  Additionally, due to variances in buffers and testing protocols 
used, each laboratory measuring samples may produce values reproducibly within a range 
of their own independent reference values, however, different from the range supplied by 
the Mayo Clinic.  In examining this enzyme for use in a natural history of disease study 
for CMD, a relatively large and heterogeneous sample size is necessary for comparison, 
due to the variances in enzyme concentration between sexes in healthy patients. 
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BUN/Creatinine measurements as a clinical blood parameter of interest. 
A significant discovery within the clinical blood chemistry of Case 1, which was 
not available for Case 2, is the constantly high levels of BUN/Creatinine measurements.  
Case 1 had BUN/Creatinine measurements provided for all but two of the twelve years 
we studied, the case file for the patient in Case 2 contained no BUN/Creatinine 
measurements. 
  BUN/Creatinine is a clinical measurement indicating the kidney’s ability to filter 
and successfully remove nitrates in the blood generated from the waste product urea, with 
respect to the relatively constant filtration of a separate muscular protein (creatinine).  
Both elevated and low measures of BUN/Creatinine are indicative of physiological 
disorders, where high BUN may be created by excess catabolism, and low BUN may 
occur as a result of excess anabolism.   
The subject in Case 1 reports high BUN/Creatinine levels in 8 out of 11 years in 
which her case has blood chemistry measurements for this parameter.  With 
BUN/Creatinine measurements gradually decreasing towards the normal reference range 
over time.  Though Case 1 repeatedly exhibits high BUN/Creatinine levels compared to 
the laboratory provided normal range, the variance between patient sample data and the 
range, is greater during early childhood, and decreases over time.  This indicates a return 
of the BUN/Creatinine level in the patient toward normal physiological levels over age.  
One possible explanation of this could be an indication of constantly recurring bone 
formation and resorption in CMD patients during the early childhood ages.  Increased 
bone resorption would produce large amounts of hydroxyproline resulting from the large 
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levels of broken down collagen.  Hydroxyproline, when further broken down by 
ubiquitination and proteolysis, would result in high levels of blood nitrogen as one of the 
end products of the catalyzed bone. 
 
Efficacy of comparing clinical data between CMD patients 
Qualitative clinical measurements, such as changes in the location and severity of 
bone hypertrophy have not been entirely reliable during this study.  In the two cases 
presented, most of the data was collected through observations collected in summaries 
from meetings with clinicians.  Clinical measurements such as the degree of hypertrophy 
of bone mass between years are qualitative measurements, made at the physician’s 
discretion.  This leads to variance in judgment between different physicians responsible 
for separate cases, as they are not abiding by a unified guide of reporting clinical 
observations. 
The ramifications of a lack of a unified procedure for reporting clinical 
observations are shown most evidently by the variation in available clinical data in the 
Reichenberger Lab CMD patient database case files (Table 4).  Available clinical data, as 
reported by Table 4, is shown to vary drastically between patient cases.  This could be 
due to physician’s judgment for which clinical data to record, hospital’s efficacy in 
maintaining patient data over time, and variances in tests conducted between years. 
Though most of the important clinical parameters determined from the literature 
were surveyed when going through the Reichenberger Lab CMD database case files, one 
important clinical characteristic overlooked, was patient bone density measurements 
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taken with age progression.  To quantitatively compare these changes in bone growth 
between patients, one suggestion would be to use radiographic measurement tools during 
CT and MR imaging to obtain precise diameters of bone thickness.  Additionally, 
quantitative measurements of MR intensity can help measure bone density.  This would 
be useful in comparing changes of bone composition over the years.  Comparison would 
then be possible between these readings and previous studies indicating soft bone in 
CMD patients [23]. 
 
Future directions for a full scale natural history of disease study of CMD 
 From this pilot study, it is concluded that a sufficient number of patients for a 
future natural history of disease study can be recruited for a retrospective study. There is 
already a large sample size of CMD patients documented within the Reichenberger Lab, 
as well as other labs publishing CMD research within the literature.  Of the 76 cases at 
the Reichenberger Lab, despite not having complete sets of clinical information, each 
case has contact information for the subject, the referring doctor, or both.  Continued 
contact will prove to be quite important for acquiring the remaining uncollected data 
within these cases.  Acquiring retrospective clinical data both descriptive and accurate 
enough for valuable comparison between cases may generate complications in continuity, 
and consistency within cases.   
Opposed to the retrospective study, continuity and consistency of data collection may 
be easier found in a prospective study.  In a future prospective natural history of disease 
study for CMD, all measurements should ideally be taken either at one clinical site, or at 
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multiple sites following one unified standard of observation, measurement, and 
documentation.  Considering many CMD patients described in the literature live abroad, 
recruitment potential to one clinical site may not be the most feasible. Having a unified 
protocol for multiple sites in different countries may is one way to collect measurements 
from CMD patients in a consistent manner. This can allow for more quantitative 
conclusions to be drawn from the data collected.  A prospective study is recommended 
over a retrospective study, for higher accuracy of collecting specific measurements. 
With different ANKH and Cx43 mutations associated with a wide range of CMD 
clinical manifestations, it may be useful to use data collected from a wider population of 
CMD patients to determine subclassifications of CMD.  This could possibly help 
preemptively predict development and progression of clinical manifestations by 
characteristics unique to each subclassification. 
 
Suggested clinical parameters for investigation 
Clinical parameters of suggestion for investigation include many of the clinical 
parameters reported in the literature.  This includes levels of blood chemistry markers, 
such as: calcium, phosphate, serum alkaline phosphatase, vitamin D, parathyroid 
hormone (PTH), calcitonin and calcitriol.  For these quantitative measurements, it is 
important to ensure testing for all blood chemistry markers and blood isoenzymes to be 
measured during routine blood work examinations, taken yearly as routinely suggested by 
general practitioners.  Consistency between measurements between patients temporally 
will help to identify any trends and commonalities.  Other clinical parameters should be 
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measured to determine CMD’s effect on bone growth.  Bone density, bone thickness, 
skull circumference, and homogeneity of the long bones are worth further investigation, 
as it has been displayed to vary over age and location in the body, within both subjects in 
this study.  A third set of clinical measurements to be made in future studies include those 
of the secondary effects of CMD.  Measurements of auditory and visual acuity should be 
taken consistently, to measure any trends in degradation of perception of either of the 
special senses, in relation to CMD.  A more detailed list of clinical parameters we suggest 
further investigation of CMD are summarized in Table 7: 
Often unmeasured aspects of CMD patients’ lives for consideration in future studies 
include the subject lifestyle choices.  Arguably the most interesting to observe would be 
diet and exercise of CMD subjects, and how both relate to the development of bone 
growth.  Of all of the CMD patients within the patient database at the Reichenberger Lab, 
only one subject case out of 76 included information on diet and exercise – a case which 
was not documented descriptively for either parameter.  Exercise is an important factor in 
bone stress, nutrient demand, and remodeling of the mesenchyme and can be an 
overlooked confounding variable in the disease progression within these subjects’ lives.  
Dietary choices also is key in nutrient availability, which may effect the manifestation of 
CMD - depending on dietary intake of associated components of CMD metabolic 
pathways, including but not limited to: calcium, inorganic phosphate, vitamin D, iron, 
magnesium.  Collection of data on diet and exercise may be hard to obtain specifically; 
however surveying subjects may be a viable alternative.  An example of some potential 
survey questions and their rationale is provided in the appendix. 
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Along with diet and exercise, other differences in lifestyle can be documented via a 
patient survey.  Seen in these two cases are the subjects’ differences in use of speech and 
sign language as forms of communication.  One potential lifestyle difference thus, may 
include choice of schooling, learning with print or braille.  
One interesting area of investigation, not nearly researched enough, is the impact of 
CMD development on mental health across all ages.  Being a disease that has so many 
secondary effects on the body, CMD has a strong psychosocial impact on the lives of 
those with the disease, especially on children.  Surveying can be a great way to 
investigate the uncharted waters of the psychosocial and psychological effects of CMD.  
Some considerations of psychosocial effects, that studies may choose to focus on are: 
dietary preferences, social anxiety, teasing, fear, headache, pain, reduced physical activity 
caused by pain, loss of sight, hearing, weak stamina and bone strength during exercise. 
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APPENDIX 
 
Suggested questions for survey investigation: 
1) Was CMD initially diagnosed or was another diagnosis suggested first? What was that 
diagnosis? 
Rationale: Ask for distribution of misdiagnosis, to show CMD differential diagnosis is 
an important issue. 
1a)  Age when bone disorder was first diagnosed. 
1b) Age at CMD diagnosis. 
1c) Complications faced as a result of this misdiagnosis. 
1d)  Clinical treatments based on misdiagnosis. 
 
2)  What information were you given about CMD when you received your diagnosis? 
Rationale:  Show need for a natural history of disease study 
2b) Physician awareness of CMD during the time of diagnosis. 
2c)  Number of referrals given before a correct diagnosis was made 
 
3) What was the treatment plan for CMD? 
Rationale:  Show wide range of treatment options used for varying CMD patients, to 
show treatment needs to be patient specific 
 3b) Patient-specific tailored treatment plans for your individually distinct CMD 
symptoms. 
 3c) Differences in treatment plans between patients 
 
4) What were your initial symptoms of CMD? 
Rationale: Determine incidence and distribution of CMD disease manifestation. 
 4a)  Changes in disease progression over time. 
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5)  Reflect on your dietary lifestyle.  List below what you would eat in an average 
breakfast, lunch, and dinner for one day. 
Rationale: Determine dietary effects on blood chemistry levels. 
 5a)  Analyze dietary decisions that may effect calcium, phosphorus, vitamin D, 
essential amino acid, protein and carbohydrate intake. 
 
6)  Have you ever had neurological problems since you’ve been born.? 
Rationale: Determine effect CMD has on visual, auditory, and proprioception acuity. 
 6a)  How have they developed over time 
6a) Determine the epigenetic details of the spread of visual, auditory, and motor 
function deficits between CMD patients. 
 
7)  Has CMD ever been a problem in your physical activity and exercise? 
Rationale: Determine if weakness in bone structure, muscle tone, or possible anemia 
secondary to CMD has exacerbated CMD’s destructive effect on sensorimotor function. 
 7a)  Analyze whether regular exercise increases bone density, bone mass, and 
bone & muscle strength, compared to subjects who do not exercise regularly. 
7B)  Determine how the biochemical pathways associated with osteogenesis and 
bone removal are compensated for, in CMD patients. 
 
Mayo Clinic pediatric alkaline phosphatase reference values 
Mayo Clinic Pediatric Test Reference Values. (2016, January 25). Retrieved from: 
http://www.mayomedicallaboratories.com/test-info/pediatric/refvalues/reference.php 
 
	60 
LIST OF JOURNAL ABBREVIATIONS 
 
Acta Otolaryngol  Acta Oto-Laryngological 
Am J Hum Genet  American Journal of Human Genetics 
Am J Med Genet A  American Journal of Medical Genetics Part A 
AMA Arch Intern Med American Medical Association's Journal of Internal 
Medicine 
Br J Ophthalmol  British Journal of Opthalmology 
Br J Plast Surg  British Journal of Plastic Surgery 
Cell Reprogram  Cellular Reprogramming 
Clin Genet    Clinical Genetics 
Dentomaxillofac Radiol Dento-maxilofacial Radiology 
Dis Nerv Sys    Diseases of the Nervous System 
Eur J Pediatr Surg  European Journal of Pediatric Surgery 
Hum Mol Gen   Human Molecular Genetics 
Indian J Pediatr  Indian Journal of Pediatrics 
J Bone Joint Surg Am  The Journal of Bone and Joint Surgery 
J Bone Miner Res  Journal of Bone and Mineral Research 
J Clin Invest   Journal of Clinical Investigation 
J Clin Psychology  Journal of Clinical Psychology 
J Laryngol Otol  The Journal of Laryngology & Otology 
J Med Gen   Journal of Medical Genetics 
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J Psychopharmacol  Journal of Psychopharmacology 
Neurol India   Neurology India 
Otol Neurotol   Otology & Neurotology 
PostGrad Med J    PostGraduate Medical Journal 
Paediatr Child Health  Journal of Paediatrics and Child Health 
Pediatr Intl   Pediatrics International 
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movement, determining perception bias through use of 
electrooculography. 
 
Skills  Laboratory: IR & NMR Spectroscopy, UV/VIS, AAC, TLC, ELISA,  
Protein Purification, Tissue Pathology, 
Gel Electrophoresis, PCR, Flow Cytometry, Assaying, ES & iPS Cell 
Culture, Immunohistochemistry. 
 
Computer: C++, MATLAB, Mathematica, Microsoft Office, 
MestReNova, ImageJ, FlowJo, InDesign, Photoshop, Social Media. 
 
Organizations Society of Asian Scientists and Engineers: Boston University Chapter 
 April 2013 – April 2015 
• Corporate Relations Chair & Social Chair. Expanded club membership 
by over 300%. 
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• Directed and organized panel lectures and networking workshops for 
undergraduate students. 
• Led my university chapter to successfully hosting the organization’s 
Northeast Regional Conference in February 2015.  
 
Publications Faik C. Meral, Michael A. Persaud, Aaron E. Silva, Abhishek Mundra, 
Greg T. Clement, Kirby G. Vosburgh, Phillip J. White. A novel device for 
guiding ventriculostomy with transcranial ultrasound. The Journal of the 
Acoustical Society of America. 04/2014; 135(5):2211. 
 
